Form 4 for PCSA Processa Pharmaceuticals, Inc.
Accepted 2026-02-04 00:00:00 ET · period of report 2026-01-01 · accession 0000897069-26-000224 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-04 | 2026-01-01 | PCSA | Young David | Pres. Research, Development, Dir | M - OptEx | $0.00 | +49 | 8,752 | +0.6% | $0 |
| D | 2026-02-04 | 2026-01-01 | PCSA | Young David | Pres. Research, Development, Dir | M - OptEx | $0.00 | -49 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-01 | M | A | 49 | $0.00 | 8,752 | D | — | — | (F1) Distribution of vested restricted shares. |
| 2 | Derivative | Restricted Stock Units | 2026-01-01 | M | D | 49 | $0.00 | 0 | D | $0.00 · — to — | 49 Common Stock | (F1) Distribution of vested restricted shares. |